Arbor Biotechnologies, Inc.

45 articles about Arbor Biotechnologies, Inc.

• 

  Allogene, Arbor Team to Develop Off-the-Shelf CAR-T Therapies with CRISPR

  3/13/2024

  Allogene Therapeutics and Arbor Biotechnologies will use their allogeneic CAR T and next-generation gene-editing platforms to develop novel off-the-shelf CAR-T therapies for autoimmune diseases.

• Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease

  3/12/2024

  Allogene Therapeutics, Inc. and Arbor Biotechnologies, Inc. today announced a non-exclusive, global gene editing licensing agreement for use of Arbor’s proprietary CRISPR gene-editing technology in Allogene’s next generation AlloCAR T platform for the treatment of autoimmune disease (AID).

• Arbor Biotechnologies Announces Collaboration with Ginkgo Bioworks to Advance the Discovery and Development of Precision Gene Editors

  12/12/2023

  Arbor today announced a collaboration with Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, to leverage Ginkgo's comprehensive Codebase and automated Foundry to jointly optimize Arbor's novel precision editors.

• Arbor Biotechnologies Appoints Industry Veteran R. Nolan Townsend to Board of Directors

  11/7/2023

  Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, announced the appointment of R. Nolan Townsend to the Company’s Board of Directors.

• Arbor Biotechnologies Appoints Ajim Tamboli as Chief Financial Officer

  8/29/2023

  Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, announced the appointment of Ajim Tamboli, CFA, as its Chief Financial Officer.

• Arbor Biotechnologies Appoints Deanna M. Petersen as Chief Business Officer

  8/7/2023

  Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, announced the appointment of Deanna M. Petersen, MBA, as its Chief Business Officer.

• Arbor Biotechnologies to Present at the Stifel 2023 Tailoring Genes: Genetic Medicines Day

  5/23/2023

  Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, announced Devyn Smith, Ph.D., Arbor’s Chief Executive Officer, will present at the Stifel 2023 Tailoring Genes: Genetic Medicines Day.

• Arbor Biotechnologies Announces Presentations at the 2023 Annual Meeting of the American Society of Gene & Cell Therapy

  5/2/2023

  Arbor Biotechnologies® today announced that three abstracts were selected for poster presentation at the upcoming American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting being held from May 16-20, 2023, in Los Angeles, CA.

• Arbor Biotechnologies Appoints Dr. Daniel Ory as Chief Medical Officer

  4/12/2023

  Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic editing medicines, announced the appointment of Daniel Ory, M.D., as Chief Medical Officer.

• Arbor Biotechnologies to Present at 2023 Cell & Gene Meeting on the Med

  4/6/2023

  Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced that Devyn Smith, Ph.D., Arbor’s Chief Executive Officer and the Chairman of Alliance for Regenerative Medicine, will give welcoming remarks and present at the annual Cell & Gene Meeting on the Med.

• 

  Vertex Leans into Gene Editing Space with Extended Arbor Pact

  1/12/2023

  Vertex and Arbor Biotechnologies extend partnership in precision gene editing.

• Arbor Biotechnologies Announces Expanded Strategic Partnership with Vertex, Now Extending to Precision Gene Editing Using Reverse Transcriptase

  1/11/2023

  Arbor Biotechnologies (Arbor) today announced the expansion of an existing strategic collaboration covering in vivo genetic medicines by which Vertex Pharmaceuticals Incorporated (Vertex) will receive rights to Arbor’s novel precision editing technology for up to three diseases.

• Arbor Biotechnologies to Present at the 41st Annual J.P. Morgan Healthcare Conference

  1/4/2023

  Arbor Biotechnologies will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 1:30 p.m. PT.

• Arbor Biotechnologies’ CEO Devyn Smith, Ph.D., Elected as Chairman of the Alliance for Regenerative Medicine

  10/20/2022

  Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, today announced that its Chief Executive Officer, Devyn Smith, Ph.D., has been elected as the Chairman of the Alliance for Regenerative Medicine (ARM), the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies.

• Arbor Biotechnologies to Participate in the 2022 Cell & Gene Meeting on the Mesa

  10/4/2022

  Arbor Biotechnologies today announced that senior management will participate in a panel discussion and present a corporate overview at the 2022 Cell & Gene Meeting on the Mesa.

• Arbor Biotechnologies to Participate in Upcoming Healthcare Investor Conferences

  9/22/2022

  Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, today announced its participation in upcoming healthcare investor conferences in September and October.

• Arbor Biotechnologies Named One of Fierce Biotech’s “Fierce 15” Companies of 2022

  9/12/2022

  Arbor Biotechnologies announced that Fierce Biotech has named it as one of 2022’s “Fierce 15” biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.

• Arbor Biotechnologies Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in Rare Liver Diseases

  8/25/2022

  Arbor Biotechnologies today announced that it has entered into an agreement with Acuitas Therapeutics, a leader in the development of lipid nanoparticles (LNP).

• Arbor Biotechnologies Appoints Lee Ann Marchionna as Chief People Officer

  8/2/2022

  Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, announced the appointment of Lee Ann Marchionna, MBA, to the newly created role of Chief People Officer.

• Arbor Biotechnologies to Present at the Bank of America Global Healthcare Conference

  5/3/2022

  Arbor Biotechnologies today announced its participation in the upcoming Bank of America Global Healthcare Conference in Las Vegas, NV.